Request Appointment
530 East 74th StreetNew York, NY 10021
Overview of Dr. Hultcrantz
Dr. Malin Hultcrantz is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Karolinska Institute Faculty of Medicine and has been in practice 14 years. She is one of 70 doctors at Memorial Sloan Kettering Cancer Center and one of 7 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Hematology. She has more than 100 publications and over 500 citings.
Education & Training
Karolinska Institute Faculty of MedicineClass of 2006
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2018 - 2027
CT State Medical License 2023 - 2026
NY State Medical License 2016 - 2026
Clinical Trials
- Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01
Roles: Contact
- A Study of Belantamab Mafodotin and Nirogacestat in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment Start of enrollment: 2022 Mar 31
Roles: Contact, Principal Investigator
- A Study of Colesevelam for Lenalidomide-Associated Diarrhea Start of enrollment: 2018 Dec 03
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Do not forget vaccinations in patients on Ig replacement.Sigrun Einarsdottir, Silvia Escribano Serrat, Marina Gomez-Llobell, Malin L Hultcrantz, Mini Kamboj
Blood Advances. 2025-09-18 - Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up Doses.Issam S Hamadeh, Lisa Modelevsky, Amelia Chan, Aaron Mitchell, Ross S Firestone
JCO Oncology Practice. 2025-09-16 - Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance.Ross S Firestone, Anish K Simhal, Devin McAvoy, Eric M Jurgens, Juan-Jose Garcés
Clinical Cancer Research. 2025-08-25
Press Mentions
- Multicenter Study of Spanish Patients Provides New Insights on COVID-19 in Multiple MyelomaNovember 11th, 2020
COVID-19 Case Fatality Rate 29 Percent in Multiple Myeloma PatientsAugust 6th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
